Monoclonal Antibody Generation
Recombinant Antibodies (Single B Cell Approach) | Hybridoma Development Overview
LAMPIRE offers comprehensive monoclonal antibody development services utilizing both traditional hybridoma technology and advanced single B cell recombinant approaches. By providing access to both platforms, we enable our clients to select the optimal strategy based on project goals, timelines, and desired antibody characteristics. Our expertise spans the full development lifecycle – from immunization through screening and characterization – delivering high-quality antibodies to support therapeutic, diagnostic, and research applications.
Monoclonal Antibody Generation
Overview
LAMPIRE offers comprehensive monoclonal antibody development services utilizing both traditional hybridoma technology and advanced single B cell recombinant approaches. By providing access to both platforms, we enable our clients to select the optimal strategy based on project goals, timelines, and desired antibody characteristics.
Our expertise spans the full development lifecycle—from immunization through screening and characterization—delivering high-quality antibodies to support therapeutic, diagnostic, and research applications.
Hybridoma Development
Key Features:
- Proven, industry-standard methodology
- Stable antibody-producing cell lines
- Suitable for long-term production needs
- Ideal for projects requiring traditional workflows
Considerations:
- Requires cell fusion, expansion, and subcloning
- Longer, more labor-intensive development timelines
- Limited sampling of the immune repertoire
- Potential loss of rare or high-value clones during processing
- Antibody sequence information is typically obtained later in development
- Single B Cell Recombinant Approach
Single B Cell Approach
LAMPIRE’s single B cell recombinant platform represents a next-generation solution for monoclonal antibody discovery. By directly isolating antigen-specific B cells from immunized animals, this approach preserves the natural immune response and accelerates development timelines.
Key Features:
- Direct isolation of antigen-specific B cells (no fusion required)
- Robust capture of the full natural immune repertoire
- Preservation of native heavy- and light-chain pairing at the single-cell level
- Rapid progression from PBMC isolation to sequence recovery and screening
- Early access to antibody sequence data (sequence-forward approach)
- Flexible recombinant expression on Fc of choice
Species & Formats:
- Proven across rabbits, llamas, alpacas, and bovine models
-
Enables discovery of:
Conventional monoclonal antibodies
vHH nanobodies
Ultralong CDR3 “picobodies” - Limited sampling of the immune repertoire
Why Choose LAMPIRE?
Dual Platform Expertise
Access to both traditional and advanced technologies
Customized Solutions
Tailored approach based on your project needs
Speed & Flexibility
Accelerated timelines with recombinant options
Diverse Species Capabilities
Expanded antibody diversity and format options
Proven Track Record
Decades of experience supporting life science innovation
Why Choose LAMPIRE?
Dual Platform Expertise
Access to both traditional and advanced technologies
Customized Solutions
Tailored approach based on your project needs
Speed & Flexibility
Accelerated timelines with recombinant options
Diverse Species Capabilities
Expanded antibody diversity and format options
Proven Track Record
Decades of experience supporting life science innovation
Research Applications
- Therapeutic antibody discovery and development
- Diagnostic assay development
- Biomarker identification and validation
- Research reagent generation
- Development of next-generation antibody formats
